✓
Open
28 Jan 2026
✓
Close
30 Jan 2026
3
Allotment
—
✓
Listing
Wed, Feb 4, 2026
Price Band
₹122 to ₹129
Issue Size
19,20,000 shares (agg. up to ₹25 Cr)
Lot Size
1,000 Shares
Listing Date
Wed, Feb 4, 2026
Latest GMP
₹68
Est. Gain
52.71%
✦ AI Insight
GMP Trend
04-02-2026₹68Est. ₹197+52.71%
03-02-2026₹68Est. ₹197+52.71%
02-02-2026₹17Est. ₹146+13.18%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 1.62x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 16.35 | 10.86 | 4.64 | 4.06 |
| Total Income | 14.07 | 16.06 | 5.20 | 3.07 |
| Profit After Tax | 2.33 | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
| NET Worth | 8.26 | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 2.95 | 4.86 | 0.72 | -0.10 |
| Total Borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹238.95 (-1.55%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹109.00 (+3.76%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹240.60 (-3.51%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹67.20 (-8.57%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹282.15 (-2.71%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹278.00 (-1.77%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹165.65 (-0.21%) |
| Amwill Health Care Ltd. | SME | ₹59.98 Cr | ₹111 | 13.81 | ₹93.25 | -15.99% | ₹43.39 (+3.04%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,062.20 (+0.04%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,439.60 (+2.37%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹168.00 (+1.44%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹14.73 (-3.22%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of Machineries for Automation in existing Manufacturing unit | 4.22 |
| 2 | Purchase of Machineries for New Manufacturing Setup | 8.03 |
| 3 | Funding working capital requirements of the Company | 5.50 |
| 4 | General Corporate Purposes | 3.69 |
| 5 | Issue Expenses | 3.33 |
| Total | 24.77 |
About Accretion Nutraveda IPO
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company operates as a Contract Development and Manufacturing Organization (CDMO), serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness. Business verticals: Domestic Sales & Merchant Exports (Loan License Basis)– contributing 96.62% of total revenue in FY 2024-25. Direct Exports– Contributing 38%, showing consistent growth. It has a manufacturing facility in Gujarat covers about 10,763 sq. ft., equipped with modern infrastructure, including 13 air handling units, separate processing areas, and quality control systems. The facility is GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certified, with an FSSAI license. Competitive Strengths Experienced promoters and management Tea
Contact Details
Accretion Nutraveda Ltd. Address27 Xcelon Industrial Park-1Vasna-ChacharwadiTaSanandAhmedabad, Gujarat, 382213+91- 9904366177compliance@accretionnutraveda.comVisit Website